Please login to the form below

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

Regeneron says antibody for COVID-19 could be ready this year

antibody discovery platform as its Ebola drug EB3, which is heading towards an FDA verdict in October. ... The update was given as Regeneron reported a 33% surge in first-quarter revenues to $1.83bn, driven by Sanofi-partnered atopic dermatitis and

Latest news

GSK seeks EU approval for Trelegy in adult asthma patients

The European Medicines Agency has accepted the regulatory submission for expanded use of GlaxoSmithKline’s Trelegy in adult asthma patients. ... Trelegy is a key drug in GSK’s arsenal, especially in its efforts to revive sales of its respiratory
Lilly expands dermatology portfolio with $1.1bn Dermira deal

Roche had been developing lebrikizumab as a potential treatment for severe asthma, but after the drug produced disappointing results in that indication decided to sell it on. ... If approved, Lilly’s newly acquired drug will closely compete with
Novartis ditches oral asthma drug after disappointing phase 3 readout

Novartis had high hopes for the drug, on the basis of the belief that by blocking the DP2 pathway, a potentially important regulator of asthma inflammation, fevipiprant (QAW039) could stabilise uncontrolled ... placebo. The strength of the data is so
Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

cancer as well as autoimmune indications, headed by a drug for solid tumours that is in a phase 1 trial. ... drug Dupixent (dupilumab) – but also failures such as dengue vaccine Dengvaxia and underperforming cholesterol drug Praluent (alirocumab).
Novartis strengthens case for its combination asthma drug

Demonstrated significant benefits in uncontrolled asthma patients. Novartis has unveiled positive phase 3 data for its dual combination asthma drug QMF149, strengthening its case for approval with regulators. . ... QMF149 also met the secondary endpoint

More from news
Approximately 2 fully matching, plus 119 partially matching documents found.

Latest Intelligence

GSK forges ahead with its dynamic COPD and asthma portfolio

You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
The long and winding road to asthma breakthroughs

This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
Cancer immunotherapy: What's on the horizon?

Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
US health reforms

In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
Building BRICs: pharma's key emerging markets are becoming giants

In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Enterprise Therapeutics appoints CEO

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
Former RBS head takes the reins as GSK chair

the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa: Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment: International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?: Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...